Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients
Authors
Keywords
<em class=EmphasisTypeItalic >MGMT</em> methylation, Glioma, <em class=EmphasisTypeItalic >IDH</em> mutation, CpG island methylator phenotype, Overall survival
Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 122, Issue 3, Pages 441-450
Publisher
Springer Nature
Online
2015-02-17
DOI
10.1007/s11060-015-1738-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors
- (2013) Pilar Mur et al. ACTA NEUROPATHOLOGICA
- MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951
- (2013) M. J. van den Bent et al. CLINICAL CANCER RESEARCH
- A pilot study of glioblastoma multiforme in elderly patients: Treatments, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status and survival
- (2013) K. Abhinav et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective
- (2013) B. Wiestler et al. NEURO-ONCOLOGY
- Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation
- (2013) W. Wick et al. NEUROLOGY
- Altered Expression of MGMT in High-Grade Gliomas Results from the Combined Effect of Epigenetic and Genetic Aberrations
- (2013) João Ramalho-Carvalho et al. PLoS One
- Can MGMT promoter methylation status be used as a prognostic and predictive marker for glioblastoma multiforme at the present time?
- (2013) R. Fietkau et al. STRAHLENTHERAPIE UND ONKOLOGIE
- MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status
- (2012) Pierre Bady et al. ACTA NEUROPATHOLOGICA
- Recent advances in the molecular understanding of glioblastoma
- (2012) Fonnet E. Bleeker et al. JOURNAL OF NEURO-ONCOLOGY
- MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors
- (2012) Marta Mellai et al. JOURNAL OF NEURO-ONCOLOGY
- Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
- (2012) Annika Malmström et al. LANCET ONCOLOGY
- Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
- (2012) Wolfgang Wick et al. LANCET ONCOLOGY
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
- (2012) Sevin Turcan et al. NATURE
- DNA methylation in glioblastoma: impact on gene expression and clinical outcome.
- (2011) Amandine Etcheverry et al. BMC GENOMICS
- A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951
- (2011) M. J. van den Bent et al. CLINICAL CANCER RESEARCH
- Predictive impact of MGMT promoter methylation in glioblastoma of the elderly
- (2011) Guido Reifenberger et al. INTERNATIONAL JOURNAL OF CANCER
- MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations
- (2011) Shani Mulholland et al. INTERNATIONAL JOURNAL OF CANCER
- MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma
- (2011) A. L. Rivera et al. NEURO-ONCOLOGY
- Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis
- (2010) Pan Du et al. BMC BIOINFORMATICS
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
- (2010) Houtan Noushmehr et al. CANCER CELL
- Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide
- (2010) Giuseppe Minniti et al. JOURNAL OF NEURO-ONCOLOGY
- Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers
- (2010) Michael Jansen et al. LANCET NEUROLOGY
- Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma
- (2009) Alba A. Brandes et al. CANCER
- MGMTPromoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951
- (2009) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
- (2009) Wolfgang Wick et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods
- (2009) Lucie Karayan-Tapon et al. JOURNAL OF NEURO-ONCOLOGY
- MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
- (2009) Michael Weller et al. Nature Reviews Neurology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now